Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis (NCT05908240)
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis: Translating Guidelines of Care to Better Outcomes for Patients With Psoriatic Disease
🩺 Plain-English Summary (8th-Grade Level)
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic — Scottsdale, Arizona
Age range: 40 Years to 75 Years
🧪 Interventions in This Study
- Care Coordinator Model (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- Mayo Clinic — Scottsdale, Arizona
- Johnson Dermatology — Fort Smith, Arkansas
- University of California, Los Angeles — Los Angeles, California
- Southern California Dermatology — Santa Ana, California
- Central Connecticut Dermatology Research — Cromwell, Connecticut
- Northwestern University — Chicago, Illinois
- Dawes Fretzin Clinical Research — Columbus, Indiana
- Dawes Fretzin Clinical Research — Indianapolis, Indiana
- AP Derm Clinical Research LLC — Somerville, Massachusetts
- MiSkinCenter — Northville, Michigan
- University of New Mexico — Albuquerque, New Mexico
- SUNY Downstate — Brooklyn, New York
- Buffalo Medical Group — Williamsville, New York
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
- City Dermatology — Bensalem, Pennsylvania
- University of Pennsylvania — Philadelphia, Pennsylvania
- University of Utah — Salt Lake City, Utah
- University of Virginia — Charlottesville, Virginia
- Bellevue Dermatology Clinic — Bellevue, Washington
- Frontier Dermatology — Mill Creek, Washington
📞 Contact the Study Coordinator
Phone: (800) 664-4580
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriasis
- Deucravacitinib Adherence Study — Winston-Salem, North Carolina
- An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
- Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
- Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
- Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
Explore by condition: All Psoriasis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.